An in Vitro Assay of hERG K+ Channel Potency for a New EGFR Inhibitor FHND004

FHND004 is a newly synthesized epidermal growth factor receptor (EGFR) inhibitor for the treatment of non-small cell lung cancer (NSCLC). The aim of the present study was to investigate the impacts of FHND004 on human ether-à-go-go-related gene (hERG) K+ channels and the molecular mechanisms underly...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Tao Jin, Bingxue Hu, Shanshan Chen, Qiang Wang, Xue Dong, Yin Zhang, Yongqiang Zhu, Zhao Zhang
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2018-05-01
Colecção:Frontiers in Pharmacology
Assuntos:
FHND004
EGFR inhibitor
human ether-à-go-go-related gene
inhibitory effect
cardiac safety
Acesso em linha:https://www.frontiersin.org/article/10.3389/fphar.2018.00577/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados